United States Generic Injectables Market 2017-2022 & Feasibility Report
DUBLIN, August 30, 2017 /PRNewswire/ --
The "US Generic Injectables Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022" report has been added to Research and Markets' offering.
The US generic injectables market reached a value of US$ 10 Billion in 2016, exhibiting a CAGR of more than 9% during 2009-2016
Over the next few years, the market is expected to be driven by a number of favourable factors. The cases of chronic diseases have been increasing on account of ageing population, sedentary lifestyles and poor eating habits. This has resulted in a heightened demand for generic injectables. Furthermore, the drug shortages in the country coupled with speedy approvals by the USFDA are expected to boost the manufacturing of these drugs. Additionally, the patent expiry of a large number of branded injectable drugs is expected to support the market growth. As a result, the market is projected to reach a value of more than US$ 16 Billion by 2022, growing at a CAGR of around 8% during 2017-2022.
The report has segmented the market on the basis of therapeutic area and covers oncology, anaesthesia, anti-infectives, parenteral nutrition, cardiovascular diseases, etc. Among these, oncology generic injectables represent the largest segment. The report has further analysed the various containers used for generic injectables including vials, premix, prefilled syringes and ampoules. On the basis of distribution channels, the report finds that hospitals dominate the market, accounting for the majority of the share. The report has also examined the competitive landscape of the market and provides the profiles of the key players operative in it. Some the major players are Hospira, Hikma, App, Sagent, Sandoz and Henry Shein, Inc.
The report also provides a comprehensive analysis for setting up a generic injectables manufacturing plant. The study analyses the processing and manufacturing requirements, project cost, project funding, project economics, expected returns on investment, profit margins, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the US generic injectables industry in any manner.
Key Topics Covered:
1 Preface
2 Scope and Methodology
3 Executive Summary
4 Introduction
5 Global Generic Drug Industry
6 US Generic Drug Industry
7 US Generic Drug Industry - Drug Delivery Systems
8 Global Generic Injectables Industry
9 US Generic Injectables Industry
10 Market by Therapeutic Area
11 Market by Containers
12 Market by Distribution Channel
13 US Generic Injectable Market: Competitive Landscape
14 Generic Injectables Manufacturing Process
15 Project Details, Requirements and Costs Involved
16 Key Players Profiles
- Hospira
- Hikma
- App
- Sagent
- Sandoz
- Henry Shein
For more information about this report visit https://www.researchandmarkets.com/research/99ptt3/us_generic
Media Contact:
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article